17-Hour Deterioration Prediction Lead from Wearables

• A wearable-based recurrent neural network (RNN with LSTM) predicted inpatient deterioration with strong discrimination (AUROC ≈ 0.89 ± 0.03; PR AUC ≈ 0.58 ± 0.14) and a median lead time of ~17 hours before Modified Early Warning Score (MEWS) alerts and ~16.5 hours before hard outcomes.

• Operational caveat for pharmacy: the multi‑hour lead time creates a proactive medication‑review window (earlier antibiotics, holding sedatives, staging emergency meds) but the model’s positive predictive value (PPV) is low (0.11–0.22 → ~80% false positives), so human triage and workflow redesign are required to avoid alert fatigue and wasted FTE effort.

• Intermittent ward vital checks miss early decline — continuous wearable monitoring detected ~9× more MEWS>6 events than episodic EHR (electronic health record) charting, with continuous respiratory rate (RR) and heart rate (HR) trends accounting for most previously missed alerts.

• For inpatient pharmacy this shifts the problem from 'catching collapses' to managing a higher volume of earlier warnings — but operational PPV (~0.11–0.22) implies ~80% false positives, so a human triage layer and tuned thresholds are essential to avoid alert fatigue and inefficient use of pharmacist time.

• Successful deployment requires clinical decision support (CDS) integration, clear triage tiers, and stewardship-aligned thresholds and staffing so scarce pharmacist FTEs focus on actionable, high‑risk patients rather than raw model alerts.

• Collected continuous wearable and EHR data from 888 adult non‑ICU inpatients (2,897 patient‑days) across four hospitals using two chest‑worn devices (VitalConnect Device #1 and Biobeat Device #2); dataset included demographics and charted vitals.

• Built an LSTM recurrent neural network (RNN) using nine inputs (age, BMI, systolic blood pressure, heart rate, respiratory rate, temperature, SpO2, MEWS, movement) on 5‑hour sequences to predict forthcoming MEWS>6 alerts (≥30 min) 0.5–24 hours ahead.

• Benchmarked against logistic regression and EHR‑only models and validated in three stages: retrospective holdout (Device #1), prospective data at a different hospital (Device #1), and external testing on a second device (Device #2); preprocessing included artifact rejection, 1‑minute resampling, simple imputation, z‑scoring, patient‑level splits, and training‑set rebalancing.

• Model performance: RNN discrimination was strong — retrospective AUROC ≈ 0.89 (±0.03) and PR AUC ≈ 0.58 (±0.14); prospective testing showed ROC 0.90 / PR 0.60; external‑device testing showed ROC 0.84 / PR 0.37.

• Timing and hard outcomes: median lead time ≈ 17 hours for predicted MEWS>6 alerts and ≈ 16.5 hours for hard outcomes; retrospectively the model detected 5/6 (83%) unplanned ICU transfers, ~50% of RRT calls, and all intubations/arrests/deaths in the limited hard‑outcome sample.

• Operational tradeoffs: Negative predictive value (NPV) was high (~0.99) but PPV was low (0.11–0.22 → ≈80% false positives), indicating the need for a central human triage layer before escalation to bedside teams; pharmacy implication — use the multi‑hour window for proactive medication review (earlier antibiotics, holding sedatives), staging emergency meds, and pre‑positioning ICU/respiratory therapies to reduce reactive code workload.

• Mechanism: continuous wearable data produced ~9× more MEWS>6 alerts than episodic charting, driven mainly by continuous respiratory rate (~71% of missed alerts) and heart rate (~16%) signals — continuous RR/HR trends enabled earlier detection independent of motion artifacts.

• Stand up a central triage layer to screen wearable‑model alerts; target an operational PPV ≈ 0.2 for escalations and route only human‑vetted, high‑credence cases to the bedside nurse and unit pharmacist for a pre‑RRT medication safety check.

• Integrate continuous vitals and the risk score into the enterprise EHR and ward dashboards (show 24‑hour RR/HR trends with the alert); route escalations via secure messaging or an inbasket triage navigator to keep reviews within workflow.

• Operationalize the 8–24‑hour window: define rapid assessment ownership, a pharmacist checklist for likely iatrogenic contributors (opioids/benzodiazepines, sedatives, electrolytes, antimicrobial gaps), and escalation aligned with existing MEWS pathways; train staff to interpret trend‑based alerts and document actions.

• Treat the system like weather radar — a probabilistic forecast requiring human confirmation: maintain governance that monitors PPV/NPV, recalibrates the model as needed, and requires human triage before treatment changes are made.

Strengths:

• Three‑stage validation (retrospective holdout, prospective separate hospital, external device) demonstrating reproducible, device‑agnostic performance across hospitals and sensors.

• Rigorous signal processing (artifact rejection, movement analysis, sampling‑rate experiments) and post‑validation recalibration improved validity and supported RR/HR‑driven early detection.

Limitations:

• Very few hard outcomes (11 total) in the dataset and non‑targeted patient patching limit training and definitive validation for ICU‑level endpoints, reducing certainty about claimed hard‑outcome performance.

• Device measurement variability, model miscalibration/overconfidence, and low operating PPV (≈0.11–0.22) require a human triage layer and local recalibration before deployment; operational burden (triage FTEs, integration) must be planned.

The wearable‑based continuous monitoring and RNN model are promising for enabling proactive pharmacy interventions by providing a multi‑hour prediction window, but the low PPV, few hard outcomes, and integration/triage needs mean this is not deployment‑ready. Pilot with human triage, local validation, threshold tuning, and EHR/CDS integration is required before broader rollout.